Predictors of severity and onset timing of immune-related adverse events in cancer patients receiving immune checkpoint inhibitors: a retrospective analysis.

Front Immunol · 2025 · PMC11876122 · PMID 40040713

Europe PMC DOI

hedged sentence

0.0510

closest p · 1.0× alpha

0.0510

boldest claim

The sentences

near-significantp=0.051so close (0.05 < p ≤ 0.1)

In contrast, univariable analysis of the imputed dataset revealed a near-significant association (OR=2.70, 95% CI: 1.00–7.31, p=0.051). 4 Discussion 4.1 Characteristics of irAEs The incidence of irAEs varies depending on cancer types, the category of ICIs, and patient-related factors.

also in 2,306 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.